Hydroxychloroquine To Ivermectin, Indians Are Self-Medicating Against COVID And It Is Dangerous
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
COVID-19: FabiFlu replaces anti-diabetic drug to become top-selling pharma brand in India
Fabiflu mops up Rs 762 cr sales in the last 12 months, higher than the anti-diabetic drug, Glycomet-GP sales of Rs 564 crore. (Image Source: ANI)
Updated: May 11, 2021, 12:58 PM IST
As India reels under a second and more deadly wave of the COVID-19 pandemic, the COVID drug FabiFlu sales witness a jump of 600% in the month of April.
Glenmark s FabiFlu, the generic version of Japanese anti-influenza drug Favipiravir is now the top-selling brand in the pharma retail market of India, data shows.
Sales of the drug which was running short of supply and saw constant SOS calls floating on social media went up by over 600% or six times, in one month.
MUMBAI: Call it the Covid effect. Anti-viral drug Favipiravir, used for Covid-19 treatment, has rocketed to the rank of the largest-selling pharma brand in April for the first time ever in the domestic retail market.
The drug, marketed by Mumbai-based Glenmark as Fabiflu, posted sales of Rs 352 crore in April alone, overtaking sales of drugs for lifestyle ailments such as diabetes, which have long dominated the market.
In April, Fabiflu overtook sales of other top-selling drugs being used in Covid-19 therapy, including health supplement Zincovit and pain-killer Dolo.
Fabiflu mops up Rs 762crore sales in last 12 months
During the pandemic, the top pecking order witnessed a change with Zincovit becoming the largestselling pharma brand in October last year, while others like Monocef, Dolo and Betadine grew at a strong clip this year.
By Dinesh Thakur Dec. 11, 2020Reprints The approval of itolizumab, a drug made by Biocon, for treating Covid-19 in India has come under fire.
Aijaz Rahi/AP
The Covid-19 pandemic has served as a stress test for drug regulators across the world. India’s has failed.
Amid the desperate scrambles for therapeutics and vaccines to stem the havoc caused by the pandemic, drug regulators have had to resist tremendous political pressure to approve unproven therapies. Rick Bright, the former head of the Biomedical Advanced Research and Development Authority (BARDA), the federal agency that helps secure the U.S. from chemical, biological, radiological, nuclear, and emerging infectious disease threats, left his position, alleging in his whistleblower complaint that he faced political pressure to allow the distribution of hydroxychloroquine, an unproven drug for treating Covid-19 that had been championed by President Trump.
vimarsana © 2020. All Rights Reserved.